Efficacy and safety of adjunctive therapy with fingolimod in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial
- 20 February 2023
- journal article
- research article
- Published by Elsevier in Schizophrenia Research
- Vol. 254, 92-98
Abstract
No abstract availableKeywords
Funding Information
- Tehran University of Medical Sciences and Health Services (52817)
This publication has 43 references indexed in Scilit:
- Brain Volumes in Schizophrenia: A Meta-Analysis in Over 18 000 SubjectsSchizophrenia Bulletin, 2012
- FingolimodCNS Drugs, 2011
- Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophreniaProgress in Neurobiology, 2011
- Fingolimod (FTY720) Enhances Remyelination Following Demyelination of Organotypic Cerebellar SlicesThe American Journal of Pathology, 2010
- Sphingosine-1-phosphate and oligodendrocytes: From cell development to the treatment of multiple sclerosisProstaglandins & Other Lipid Mediators, 2010
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple SclerosisClinical Neuropharmacology, 2010
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Correlates of cognitive impairment in first episode schizophrenia: The EUFEST studySchizophrenia Research, 2009
- SchizophreniaThe Lancet, 2009
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960